VORTIOXETINE | VORTIOXETINE | ATC N06AX26
NERVOUS SYSTEM TREATMENT OF MAJOR DEPRESSIVE DISORDER ENHANCEMENT OF SEROTONERGIC ACTIVITY INHIBITION OF THE REUPTAKE OF SEROTONIN (5-HT) SEROTONIN TRANSPORTER INHIBITOR (KI=1.6 NANOMOLAR) 5-HT3 RECEPTOR ANTAGONIST (KI=3.7 NANOMOLAR) AND 5-HT1A RECEPTOR AGONIST (KI=15 NANOMOLAR), 5-HT7 (KI=19 NM), 5-HT1D (KI=54 NM), AND 5-HT1B (KI=33 NM), RECEPTORS AND IS A 5-HT3, 5-HT1D, AND 5-HT7 RECEPTOR ANTAGONIST, 5-HT1B RECEPTOR PARTIAL AGONIST, AND 5-HT1A RECEPTOR AGONIST. | ORAL | Cmax 110 NANOMOLAR F 75 PERCENT VD 2600 LITER PPB 98 PERCENT Cl 27.3 LITER / HOUR (EQN) HT 66 HOUR SOLUBILITY SLIGHTLY SOLUBLE IN WATER | SEROTONIN TRANSPORTER | SEROTONIN 1A (5-HT1A) RECEPTOR AGONIST CHEMBL214 SEROTONIN 1A (5-HT1A) RECEPTOR P08908 5-HYDROXYTRYPTAMINE RECEPTOR 1A HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR SEROTONIN RECEPTOR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |